Story perspectives
Beta-Blockers Show Mixed Heart Benefits in Trials
8/31/2025
29 5
1 of 1
Story summary
- Recent trials in Madrid produced mixed results on beta-blockers for heart attack patients.
- The BETAMI–DANBLOCK trial indicated a 15% reduced risk of serious cardiovascular events in patients with mildly impaired heart function.
- Conversely, the REBOOT trial showed no significant benefits for patients with normal heart function.
- Further research is underway to resolve these conflicting findings.
